Company Directory - Adaptive Biotechnologies Corporation
Company Details - Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation
WebsiteSeattle, United States
ISIN: US0079031072
Adaptive Biotechnologies Corporation is a biotechnology company specializing in immune-driven medicine. They utilize proprietary technologies to decode the adaptive immune system, facilitating new therapies and diagnostics for a range of diseases.
CCI Score
CCI Score: Adaptive Biotechnologies Corporation
-23.78
0.02%
Latest Event
Adaptive Biotechnologies workforce reduction amid restructuring
Adaptive Biotechnologies Corporation has laid off around 100 workers, approximately 12% of its workforce, as part of a strategic restructuring to focus on core areas of minimal residual disease and immune medicine. The decision raises concerns regarding the company’s commitment to worker rights.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Adaptive Biotechnologies Corporation is currently rated as an Accomplice.
Latest Events
- APR292025
Adaptive Biotechnologies Corporation has laid off around 100 workers, approximately 12% of its workforce, as part of a strategic restructuring to focus on core areas of minimal residual disease and immune medicine. The decision raises concerns regarding the company’s commitment to worker rights.
-40
Labor Relations and Human Rights Practices
April 4
The decision to lay off 12% of the workforce demonstrates a detrimental impact on labor relations and worker rights. This restructuring prioritizes streamlining operations over the welfare of employees, reflecting negative practices in labor relations and ethical responsibility.
Adaptive Biotechnologies lays off 12% of workforce to narrow immunosequencing tech
- FEB062025
The OpenSecrets profile indicates that Adaptive Biotechnologies contributed $7,005 during the 2024 cycle and reported no lobbying or outside spending, reflecting a low level of political engagement and minimal risk of facilitating authoritarian agendas.
+15
Political Contributions and Lobbying Efforts
April 4
Adaptive Biotechnologies' limited contribution of $7,005 and absence of lobbying spending suggest a restrained approach to political financing. This modest political engagement is unlikely to fuel far‐right or authoritarian ideologies, and thus is assessed with a positive, though modest, anti‐fascist score.
- JAN012024
OpenSecrets data reveals a profile for Adaptive Biotechnologies that details its annual lobbying totals since 1998. The profile also notes that the company has not reported lobbying on specific bills in 2024, raising questions about its ongoing political influence and transparency.
-20
Political Contributions and Lobbying Efforts
April 4
The OpenSecrets profile documents Adaptive Biotechnologies’ engagement in lobbying as a longstanding practice. Although the company has not reported lobbying on specific bills in 2024, the sustained effort to influence policy is concerning from a democratic accountability perspective. Corporate lobbying activities can undermine transparency and potentially support dynamics that favor authoritarian influence.
- DEC312023
Adaptive Biotechnologies spent $80,000 on federal lobbying in 2023 as reported by OpenSecrets, indicating active corporate political engagement.
-30
Political Contributions and Lobbying Efforts
April 4
The reported $80,000 in lobbying expenditures suggests that Adaptive Biotechnologies is actively engaging in corporate political activity. From an anti-fascist perspective, such engagement is concerning because corporate lobbying can skew public policy towards corporate interests and undermine democratic accountability, thereby potentially supporting authoritarian influences.
- JAN012023
An OpenSecrets report reveals that Adaptive Biotechnologies spent $200,000 on lobbying in 2023, reflecting an effort to influence public policy that may benefit corporate interests over democratic accountability.
-40
Political Contributions and Lobbying Efforts
April 4
The reported $200,000 lobbying expenditure underscores the company's active engagement in shaping public policy. From an anti-fascist perspective, such corporate lobbying can be seen as prioritizing corporate interests and potentially undermining democratic accountability and workers' rights.
- JAN012023
Adaptive Biotechnologies spent $200,000 on lobbying activities in 2023, as tracked by OpenSecrets. The expenditure raises concerns about potential corporate influence on policy-making without adequate transparency on the issues lobbied.
-50
Political Contributions and Lobbying Efforts
April 4
The disclosure that Adaptive Biotechnologies spent $200,000 on lobbying in 2023 suggests a deliberate effort to influence political processes. From an anti-fascist perspective, such corporate lobbying, conducted without clear transparency on the targeted issues, can undermine democratic accountability and bolster corporate interests at the expense of public welfare.
- MAR092022
Adaptive Biotechnologies Corporation announced a restructuring initiative that involves laying off 100 of its 850 employees. The move, confirmed by CEO Chad Robins, was described as a difficult but necessary decision to streamline the company, even as it raises concerns about the impact on worker security.
-35
Labor Relations and Human Rights Practices
April 4
The decision to lay off 100 workers as part of a cost-cutting and restructuring effort negatively affects employee job security and raises issues related to fair labor practices. Although the CEO defended the move as necessary for operational efficiency, it reflects a disregard for worker rights, warranting a negative score under the Labor Relations and Human Rights Practices category.
Billion-dollar Seattle company Adaptive Biotechnologies lays off 100
Alternatives
Corporation
-21.31
Boston, United States
39.22
Cambridge, United States
-13.08
Zug, Switzerland
22.95
Corporation
27.23
Corporation
9.63
Corporation
0.00
Corporation
0.00
Ithaca, United States
63.86
New York City, United States
23.18
Corporate Financials
- Revenue
- 2022
- $116.00M
- Total Assets
- 2022
- $460.00M
- Operating Income
- 2022
- -$21.50M
- Total Equity
- 2022
- $326.00M
Industries
- 541713
- Research and Development in Nanotechnology
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories